Patents,Pipeline Products
Patents for CM101 in Cancer, Wound Healing including neural injury, Chronic Inflammatory Diseases, Vaccines, Diagnostics

TumorEnd®-Licensed Patent Portfolio

Patents for Composition of Matter:

Purification Methods Patents:   These 4 patents constitute composition of matter for the CM101 polysaccharide, and are considered among the strongest IP protection for the CM101 therapeutic technology.

5,811,403             Purification Method             Sep. 30, 1996            Sep. 22, 1998

Title: Polysaccharide Toxin from Group B b-Hemolytic Streptococcus (GBS) Having Improved Purity. C.G. Hellerqvist,

 

5,939,396            Purification Method            Feb. 24, 1998            Aug. 17, 1999

Title: Methods for Purifying GBS Toxin/CM101. C. G. Hellerqvist,

6,136,789             Purification Method            Mar. 19, 1998            Oct. 24, 2000

Title: Polysaccharide Toxin from Group B b-Hemolytic Streptococcus (GBS) Having Improved Purity. C.G. Hellerqvist

 

6,407,069             Purification Method            Mar. 30, 1999            Jun. 18, 2002

NOTE: Patent '069 is valid through 2022, however, since biologicals have 12 years of protection AFTER FDA approval, if approval were granted, for example in 2014, the patent would be valid through 2026.

RECEPTOR PATENT: (Most relevant protection of the technology of capillary disruption).

6,803,448            CM101 Receptor                         Jul. 21, 1999                        Oct. 12, 2004

This patent covers the HP59 receptor and any compounds that initiate an immune initiation, including CM101, antibodies, small molecules.  This patent offers protection through 2026-2028, at least, depending on 12 years after approval by the FDA.

Title: Methods for Purifying GBS Toxin/CM101.

Relevant Publications:

 

Sundell HW, Yan H-P, Wamil BD, Carter CE, Stahlman MT, Hellerqvist CG. Isolation and identification of a Group B b-hemolytic streptococcal toxin from septic infants. J Pediatrics 137:338-344 (2000).

 

Tumor Therapeutics, including Phase I Clinical Trial:

Relevant Publications:

Hellerqvist CG, Thurman GB, Page DL, Wang Y-F, Russell BA, Montgomery CA, Sundell HW: Anti-tumor effects of GBS toxin: A polysaccharide exotoxin from Group B beta-hemolytic streptococcus. Canc Res Clin Oncol 120, 63-70 (1993).

Thurman GB, Russell BA, York GE, Wang Y-F, Page DL, Sundell HW, Hellerqvist CG: Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors. J Canc Res Clin Oncol 120, 479-484 (1994).

Thurman GB, Page DL, Wamil BD, Wilkinson LE, Kasami M, Hellerqvist CG: Acute inflammatory changes in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS toxin). J Canc Res Clin Oncol, 122, 549-553 (1996).

Yan H-P, Carter CE, Wang E-Z, Page DL, Washington K, Wamil BW, Yakes FM, Thurman GB, and Hellerqvist, CG: Functional studies on the anti-pathoangiogenic properties of CM101. Angiogenesis 2, 219-233 (1998).

Yakes FM, Wamil BD, Sun F, Yan H-P, Carter CE and Hellerqvist CG: CM101 treatment overrides tumor induced immunoprivilege leading to apoptosis. Cancer Research 60:5740-5746 (2000).

Phase I Clinical Trial on CM101:  Phase I, IND-based.

DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan H-P, Carter CE, Wang Y-F, York GE, Zhang M-H, Johnson DH.: A phase I study of the antineovascularization drug CM101. J Clin Canc Res, 3, 365-372 (1997).

Wamil BD, Thurman GB, DeVore RF, Wakefield G, Johnson DH, Hellerqvist CG: Soluble E-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial.

Wamil BD, Thurman GB, DeVore RF, Wakefield G, Johnson DH, Hellerqvist CG: Soluble E-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial.

 

PRODUCT:  CM101 as a solid tumor therapeutic based on immune attack against tumor neovasculature angiogenesis.   The mechanism is complement activation and recruitment of activated granulocytes.

Market Size:  Estimated $4B, USA

 

Patents covering wound healing and reduced scar formation in cosmetic and reconstructive surgery.

 

5,858,991             Wound Healing                                                             Jan. 12, 1999

Title: Facilitation of Wound Healing with CM101/GBS Toxin. C.G. Hellerqvist, B.D. Wamil, M. Neeman and R. Abramovitch

Relevant publications: 

 

Quinn TE, Thurman GB, Sundell A-K, Zhang M, Hellerqvist CG: CM101, a polysaccharide anti-tumor agent, does not inhibit wound healing In murine models. J Canc Res Clin Oncol, 121, 253-256 (1995).

 

Nanney, L.B.; Wamil, B.D.; Whitsitt, J.; Cardwell, N.L.; Davidson, J.M.; Yan, H.-P.; Hellerqvist, C.G. (2001). "CM101 Stimulates Cutaneous Wound Healing Through an Anti-Angiogenic Mechanism". Angiogenesis 4 (1): 61–70. doi:10.1023/A:1016752925761.PMID 11824380.

6,569,838             Keloid Healing                                                    May 27, 2003

Title: Facilitation of Keloid healing with CM101/GBS toxin. C.G. Hellerqvist, B.D. Wamil, M. Neeman and R. Abramovitch,

 

PRODUCT:  CM101 as a scar-reducing therapeutic for cosmetic plastic and reconstructive surgery.

Market:  Estimated $1B


Patents covering Spinal Cord Injury and other neural injury therapeutics.

5,981,508            Repair of Neural Injury            Jan. 29, 1997             Nov. 09, 1999

Title: Facilitation of Repair of Neural Injury with CM101/GBS Toxin. C.G. Hellerqvist, A.W. Wamil and B.D.Wamil.

 

Relevant publications:

Wamil AW, Wamil BD, Hellerqvist CG: CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury. Proc Natl Acad Sci USA 95, 13188-13193 (1998).

 

6,476,001            Repair of Neural Injury            Jul. 29, 1999                        Nov. 05, 2002

Relevant publications:

Ohlsson M, Mattson P, Wamil BD, Hellerqvist CG, Svenson M. Macrophage stimulation using a Group B streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve. Restorative Neurology and Neuroscience. 22: 33-41 (2004)

 

Wamil AW, Wamil BD, Hellerqvist CG: CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury. Proc Natl Acad Sci USA 95, 13188-13193 (1998).

 

PRODUCT:  CM101 as a therapeutic for spinal cord injury.

Market:  Estimated $1B

 

PRODUCT:  CM101 as a therapeutic for spinal cord injury.

Market:  Estimated $1B

 

Patents covering therapeutics in diseases of inflammation:

 

6,670,337             Reperfusion Injury                                               Dec. 30, 2003

6,476,002             Application to Chronic Inflammatory Diseases               Nov. 05, 2002

                      

PRODUCT:  CM101 as a therapeutic for rheumatoid arthritis and other autoimmune disorders.

Market:  Estimated $1B


Patents covering anti-tumor vaccines and therapeutic antibody biologicals for tumor vasculature targeting.

6,803,448            CM101 Receptor                         Jul. 21, 1999                        Oct. 12, 2004

GBS Toxin Receptor.(HP59 peptide sequences)C.G. Hellerqvist and Changlin Fu.

Relevant publications:

Fu C, Bardhan S, Cetateanu ND, Wamil BD, WangY, Yan H-P, Carter CE, Shi E, Venkov C, Yakes FM, Page DL, Lloyd RS, Hellerqvist CG. Identification of a novel membrane protein HP59 with therapeutic potential as a target of tumor angiogenesis. Clin. Cancer Research 7:4182-4194 (2001).

 

PRODUCT: Vaccine:   HP59 peptides used as a vaccine to prevent any solid tumor angiogenesis in humans.    The vaccine could be effective on both diagnosed and future cancers.   This technology is revolutionary, has been demonstrated in mice, will require one more animal preclinical.

Market:  Estimated $4B

7,410,640            HP59 Antibodies                        Apr. 12, 2004            Aug. 12, 2008

Title: GBS Toxin Receptor antibodies C.G. Hellerqvist and Changlin Fu

Relevant publications:

Fu C, Bardhan S, Cetateanu ND, Wamil BD, WangY, Yan H-P, Carter CE, Shi E, Venkov C, Yakes FM, Page DL, Lloyd RS, Hellerqvist CG. Identification of a novel membrane protein HP59 with therapeutic potential as a target of tumor angiogenesis. Clin. Cancer Research 7:4182-4194 (2001).

 

PRODUCT:  Therapeutic for Solid Tumors, activity similar to CM101.

Market:  ($4B shared with CM101, since they address the same target).

PRODUCT:   Diagnostic for Solid Tumors, imaging of HP59 Antibody targets using labels such as for PET or SPECT scans

Market:   $0.5 B

 

Pending Patents:  In process.

GBS Toxin Receptor Protein and DNA Sequences. C.G. Hellerqvist and C. Fu. U.S. Patent Application Serial No. 60/093,843. Total of 12 anticipated patents.

 

Methods for Preventing or Attenuating Pathoangiogenic Conditions. C.G. Hellerqvist. U.S. C0779-2062.